News Breaks |
|
|
| January 11, 2013 |
| 06:13 EDT |  | FRX | Forest Labs upgraded to Neutral from Sell at Goldman
Goldman upgraded Forest Laboratories to reflect potential earnings growth from new launches or restructurings. Price target is $40. |
|
|
News For FRX From The Last 14 Days Check below for free stories on FRX the last two weeks. |
|
|
| May 23, 2013 |
| 08:10 EDT |  | FRX | Forest Labs says Howard Solomon to retire as CEO, President at year end
Forest Laboratories announced that Howard Solomon will retire as Chief Executive Officer and President, effective December 31, 2013. Subject to the same nominating and election processes annually as all directors, Solomon is expected to remain as Chairman through the 2014 Annual General Meeting, at which time another Chairman will be elected. Solomon will retain the title of Chairman Emeritus after the 2014 AGM and has agreed to serve as Senior Advisor to the Company following his retirement as CEO and President. As previously disclosed, an independent committee of Forest’s Board has been engaged in a succession planning process, including evaluating internal and external candidates. With Solomon’s retirement announcement, the Board has determined to bring the process to a close and expects to name a successor before the end of the year. The committee is being assisted by executive search firm Spencer Stuart, the company said. |
|
| 08:04 EDT | | FRX | Forest Labs says Howard Solomon to retire as CEO, President at year end
 Subscribe for More Information |
|
| May 20, 2013 |
| 07:28 EDT |  | FRX | American Thoracic Society to hold a conference
Subscribe for More Information |
|
| 07:27 EDT | | FRX | American Psychiatric Association to host annual meeting
Subscribe for More Information |
|
| May 17, 2013 |
| 10:36 EDT | | FRX | Leerink's major/specialty pharma analyst holds analyst/Industry conference call
Subscribe for More Information |
|
| May 10, 2013 |
| 10:00 EDT |  | FRX | On The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: 3D Systems (DDD) initiated with a Buy at Janney Capital... Actavis (ACT) initiated with an Outperform at BMO Capital... Allergan (AGN) initiated with an Outperform at BMO Capital... Emeritus (ESC) initiated with an Outperform at Wells Fargo... Ensign Group (ENSG) initiated with a Market Perform at Wells Fargo... Forest Labs (FRX) initiated with an Underperform at BMO Capital... J2 Global (JCOM) initiated with an Outperform at Wedbush... Mylan (MYL) initiated with an Underperform at BMO Capital... Splunk (SPLK) initiated with a Market Perform at FBR Capital... Teva (TEVA) initiated with an Outperform at BMO Capital... Workday (WDAY) initiated with an Outperform at Oppenheimer... Nuance (NUAN) initiated with an Outperform at Wedbush... Demandware (DWRE) initiated with an Outperform at Wedbush... Synchronoss (SNCR) initiated with an Outperform at Wedbush... Trius Therapeutics (TSRX) initiated with a Buy at Guggenheim... Proto Labs (PRLB) initiated with a Buy at Janney Capital... Stratasys (SSYS) initiated with a Buy at Janney Capital. |
|
| May 9, 2013 |
| 16:34 EDT | | FRX | Forest Labs initiated with an Underperform at BMO Capital
Subscribe for More Information |
|
| 06:05 EDT | | FRX | Forest Labs and Trevene to co-develop TRV027 for acute heart failure
Subscribe for More Information |
|
|
|
|
|
